格列奈胰岛素治疗 1 型糖尿病:回顾二十年来的临床试验和现实世界的证据。

IF 2.4 Q3 ENDOCRINOLOGY & METABOLISM Current diabetes reviews Pub Date : 2024-01-01 DOI:10.2174/1573399819666230310150905
Banshi Saboo, Hemraj Chandalia, Sujoy Ghosh, Jothydev Kesavadev, I P S Kochar, K M Prasannakumar, Archana Sarda, Ganapathi Bantwal, R N Mehrotra, Madhukar Rai
{"title":"格列奈胰岛素治疗 1 型糖尿病:回顾二十年来的临床试验和现实世界的证据。","authors":"Banshi Saboo, Hemraj Chandalia, Sujoy Ghosh, Jothydev Kesavadev, I P S Kochar, K M Prasannakumar, Archana Sarda, Ganapathi Bantwal, R N Mehrotra, Madhukar Rai","doi":"10.2174/1573399819666230310150905","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Over the past two decades, insulin glargine 100 U/mL (Gla-100) has emerged as the \"standard of care\" basal insulin for the management of type 1 diabetes mellitus (T1DM). Both formulations, insulin glargine 100 U/mL (Gla-100) and glargine 300 U/mL (Gla- 300) have been extensively studied against various comparator basal insulins across various clinical and real-world studies. In this comprehensive article, we reviewed the evidence on both insulin glargine formulations in T1DM across clinical trials and real-world studies.</p><p><strong>Methods: </strong>Evidence in T1DM for Gla-100 and Gla-300 since their approvals in 2000 and 2015, respectively, were reviewed.</p><p><strong>Results: </strong>Gla-100 when compared to the second-generation basal insulins, Gla-300 and IDeg-100, demonstrated a comparable risk of overall hypoglycemia, but the risk of nocturnal hypoglycemia was higher with Gla-100. Additional benefits of Gla-300 over Gla-100 include a prolonged (>24- hours) duration of action, a more stable glucose-lowering profile, improved treatment satisfaction, and greater flexibility in the dose administration timing.</p><p><strong>Conclusion: </strong>Both glargine formulations are largely comparable to other basal insulins in terms of glucose-lowering properties in T1DM. Further, risk of hypoglycemia is lower with Gla-100 than Neutral Protamine Hagedorn but comparable to insulin detemir.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":"e100323214554"},"PeriodicalIF":2.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10909813/pdf/","citationCount":"0","resultStr":"{\"title\":\"Insulin Glargine in Type 1 Diabetes Mellitus: A Review of Clinical Trials and Real-world Evidence Across Two Decades.\",\"authors\":\"Banshi Saboo, Hemraj Chandalia, Sujoy Ghosh, Jothydev Kesavadev, I P S Kochar, K M Prasannakumar, Archana Sarda, Ganapathi Bantwal, R N Mehrotra, Madhukar Rai\",\"doi\":\"10.2174/1573399819666230310150905\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Over the past two decades, insulin glargine 100 U/mL (Gla-100) has emerged as the \\\"standard of care\\\" basal insulin for the management of type 1 diabetes mellitus (T1DM). Both formulations, insulin glargine 100 U/mL (Gla-100) and glargine 300 U/mL (Gla- 300) have been extensively studied against various comparator basal insulins across various clinical and real-world studies. In this comprehensive article, we reviewed the evidence on both insulin glargine formulations in T1DM across clinical trials and real-world studies.</p><p><strong>Methods: </strong>Evidence in T1DM for Gla-100 and Gla-300 since their approvals in 2000 and 2015, respectively, were reviewed.</p><p><strong>Results: </strong>Gla-100 when compared to the second-generation basal insulins, Gla-300 and IDeg-100, demonstrated a comparable risk of overall hypoglycemia, but the risk of nocturnal hypoglycemia was higher with Gla-100. Additional benefits of Gla-300 over Gla-100 include a prolonged (>24- hours) duration of action, a more stable glucose-lowering profile, improved treatment satisfaction, and greater flexibility in the dose administration timing.</p><p><strong>Conclusion: </strong>Both glargine formulations are largely comparable to other basal insulins in terms of glucose-lowering properties in T1DM. Further, risk of hypoglycemia is lower with Gla-100 than Neutral Protamine Hagedorn but comparable to insulin detemir.</p>\",\"PeriodicalId\":10825,\"journal\":{\"name\":\"Current diabetes reviews\",\"volume\":\" \",\"pages\":\"e100323214554\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10909813/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current diabetes reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1573399819666230310150905\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current diabetes reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573399819666230310150905","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

背景:在过去 20 年中,格列美脲胰岛素 100 U/mL(Gla-100)已成为治疗 1 型糖尿病(T1DM)的 "标准护理 "基础胰岛素。在各种临床和实际研究中,格列卫胰岛素 100 U/mL(Gla-100)和格列卫胰岛素 300 U/mL(Gla- 300)这两种制剂与各种比较基础胰岛素进行了广泛的对比研究。在这篇综述性文章中,我们回顾了临床试验和实际研究中两种格列卫胰岛素制剂在 T1DM 中的应用证据:方法:分别回顾了 Gla-100 和 Gla-300 自 2000 年和 2015 年获批以来在 T1DM 中的应用证据:结果:Gla-100与第二代基础胰岛素Gla-300和IDeg-100相比,总体低血糖风险相当,但Gla-100的夜间低血糖风险更高。与 Gla-100 相比,Gla-300 的其他优点还包括作用时间更长(超过 24 小时)、降糖谱更稳定、治疗满意度更高以及给药时间更灵活:结论:两种格列奈制剂在治疗 T1DM 时的降糖特性与其他基础胰岛素基本相当。此外,格列-100 的低血糖风险低于中性丙种球蛋白,但与胰岛素地特米不相上下。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Insulin Glargine in Type 1 Diabetes Mellitus: A Review of Clinical Trials and Real-world Evidence Across Two Decades.

Background: Over the past two decades, insulin glargine 100 U/mL (Gla-100) has emerged as the "standard of care" basal insulin for the management of type 1 diabetes mellitus (T1DM). Both formulations, insulin glargine 100 U/mL (Gla-100) and glargine 300 U/mL (Gla- 300) have been extensively studied against various comparator basal insulins across various clinical and real-world studies. In this comprehensive article, we reviewed the evidence on both insulin glargine formulations in T1DM across clinical trials and real-world studies.

Methods: Evidence in T1DM for Gla-100 and Gla-300 since their approvals in 2000 and 2015, respectively, were reviewed.

Results: Gla-100 when compared to the second-generation basal insulins, Gla-300 and IDeg-100, demonstrated a comparable risk of overall hypoglycemia, but the risk of nocturnal hypoglycemia was higher with Gla-100. Additional benefits of Gla-300 over Gla-100 include a prolonged (>24- hours) duration of action, a more stable glucose-lowering profile, improved treatment satisfaction, and greater flexibility in the dose administration timing.

Conclusion: Both glargine formulations are largely comparable to other basal insulins in terms of glucose-lowering properties in T1DM. Further, risk of hypoglycemia is lower with Gla-100 than Neutral Protamine Hagedorn but comparable to insulin detemir.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current diabetes reviews
Current diabetes reviews ENDOCRINOLOGY & METABOLISM-
CiteScore
6.30
自引率
0.00%
发文量
158
期刊介绍: Current Diabetes Reviews publishes frontier reviews on all the latest advances on diabetes and its related areas e.g. pharmacology, pathogenesis, complications, epidemiology, clinical care, and therapy. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians who are involved in the field of diabetes.
期刊最新文献
Development and Novel Therapeutics in Diabetic Retinopathy. The Effect of COVID-19 Lockdown Among Adolescents with Type 1 Diabetes: A Systematic Review and Meta-Analysis. Ultrasound Evaluations of Ankle and Foot Muscles in Diabetic Peripheral Neuropathy Systematic Review with Meta-Analysis. In-Vitro and In-Silico Studies of Brevifoliol Ester Analogues against Insulin Resistance Condition. Efficacy of Adjunctive Local Antimicrobials to Non-Surgical Periodontal Therapy in Pocket Reduction and Glycemic Control of Patients with Type 2 Diabetes: A Network Meta-Analysis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1